Services
Where scientific depth meets strategic clarity.
Aklyva provides targeted advisory across the full conjugate and payload development continuum — from first-in-class concept through to IND-enabling studies and CRO campaign governance.
Payload Strategy & Optimisation
Rigorous, SAR-driven advisory on cytotoxic and novel payload selection, linker chemistry design, and therapeutic index optimisation.
Payload selection is the single most consequential decision in a conjugate programme. Aklyva brings deep medicinal chemistry expertise to warhead identification, potency-selectivity profiling, and linker-payload compatibility assessment. We evaluate cleavable and non-cleavable linker architectures against target biology, tumour microenvironment, and manufacturability constraints — ensuring the payload strategy is defensible at every stage from discovery through to IND.
Capabilities
- First-in-class warhead identification and competitive landscape analysis
- Linker chemistry design and SAR-driven optimisation
- Therapeutic index modelling and bystander effect assessment
- Payload manufacturability and synthetic accessibility review
Antibody-Drug Conjugates
End-to-end ADC programme advisory spanning conjugation platform selection, DAR control, site-specific approaches, and analytical characterisation strategy.
Aklyva has guided multiple ADC programmes from platform selection through clinical-stage development. Our advisory covers the full technical breadth of the field: stochastic versus site-specific conjugation, DAR distribution control, aggregation mitigation, and the analytical package required to support regulatory submissions. We work alongside internal teams and CROs to ensure scientific rigour is maintained across every programme milestone.
Capabilities
- Conjugation platform selection and technical due diligence
- DAR control strategy and site-specific conjugation approaches
- Analytical characterisation package design (HIC, SEC, MS, HIC-MS)
- CMC strategy and IND-enabling study design
- CRO technical oversight and milestone governance
Peptide Conjugates
Targeted peptide-drug conjugate design integrating receptor biology, peptide stability engineering, and conjugation site selection for GLP-1, oncology, and beyond.
Peptide-drug conjugates represent a rapidly expanding modality with distinct design challenges. Aklyva provides advisory on receptor-targeting vector selection, peptide stability engineering (cyclisation, non-natural amino acids, PEGylation), and conjugation site optimisation to preserve receptor affinity while enabling efficient drug attachment. Our experience spans GLP-1 receptor agonist conjugates, tumour-targeting peptide vectors, and cell-penetrating peptide platforms.
Capabilities
- Receptor biology integration and targeting vector selection
- Peptide stability engineering and half-life extension strategies
- Conjugation site selection and linker compatibility assessment
- GLP-1 and metabolic disease conjugate programme advisory
- Oncology peptide-drug conjugate design and optimisation
Outsourced Synthetic Chemistry
Strategic management of CRO and CDMO chemistry campaigns — vendor selection, technical due diligence, milestone governance, and IP protection across distributed synthesis networks.
Outsourcing synthetic chemistry is operationally complex and scientifically high-risk without experienced oversight. Aklyva manages the full campaign lifecycle: from CRO/CDMO identification and technical capability assessment through to contract negotiation support, milestone definition, data quality governance, and IP protection strategy. We act as the scientific interface between your internal team and external partners, ensuring programme continuity and rigour regardless of geography.
Capabilities
- CRO and CDMO identification, capability assessment, and selection
- Technical due diligence and scientific fit evaluation
- Milestone definition, governance frameworks, and progress review
- Data quality standards and analytical acceptance criteria
- IP protection strategy and confidentiality framework design
How We Work
Structured engagements. Defined outcomes.
Programme Review
A focused, time-limited assessment of your current programme — payload strategy, conjugation approach, or CRO campaign — with a written report and prioritised recommendations.
Embedded Advisory
Ongoing scientific advisory integrated with your internal team. Typically structured as a defined number of days per month, with clear deliverables and regular review cadence.
Investor Due Diligence
Independent technical assessment of a conjugate or payload programme for investment or acquisition purposes. Rigorous, impartial, and delivered to institutional standard.
Discuss your programme.
Every engagement begins with a confidential conversation about your programme's current position and where expert advisory would have the greatest impact.